Carol Fraser‐Browne

1.1k total citations · 1 hit paper
13 papers, 380 citations indexed

About

Carol Fraser‐Browne is a scholar working on Pulmonary and Respiratory Medicine, Radiation and Surgery. According to data from OpenAlex, Carol Fraser‐Browne has authored 13 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 5 papers in Radiation and 2 papers in Surgery. Recurrent topics in Carol Fraser‐Browne's work include Prostate Cancer Diagnosis and Treatment (6 papers), Prostate Cancer Treatment and Research (5 papers) and Advanced Radiotherapy Techniques (5 papers). Carol Fraser‐Browne is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (6 papers), Prostate Cancer Treatment and Research (5 papers) and Advanced Radiotherapy Techniques (5 papers). Carol Fraser‐Browne collaborates with scholars based in New Zealand, Australia and United Kingdom. Carol Fraser‐Browne's co-authors include Andrew Kneebone, Maria Pearse, Mahesh Parmar, Silvia Forcat, Pierre Richaud, Jayne F. Tierney, Meryem Brihoum, Paul Sargos, Sylvie Chabaud and Matthew R. Sydes and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Carol Fraser‐Browne

13 papers receiving 378 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data

2020 185 citations Claire L. Vale, David J. Fisher et al. The Lancet profile →

Peers

Countries citing papers authored by Carol Fraser‐Browne

Since Specialization

Citations

This map shows the geographic impact of Carol Fraser‐Browne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol Fraser‐Browne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol Fraser‐Browne more than expected).

Fields of papers citing papers by Carol Fraser‐Browne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol Fraser‐Browne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol Fraser‐Browne. The network helps show where Carol Fraser‐Browne may publish in the future.

Co-authorship network of co-authors of Carol Fraser‐Browne

This figure shows the co-authorship network connecting the top 25 collaborators of Carol Fraser‐Browne. A scholar is included among the top collaborators of Carol Fraser‐Browne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol Fraser‐Browne. Carol Fraser‐Browne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data breakdown → 2020 ·The Lancet ·Claire L. Vale, David J. Fisher, Andrew Kneebone, Christopher Parker, Maria Pearse, Pierre Richaud, Paul Sargos, Matthew R. Sydes, Chris Brawley, Meryem Brihoum, Chris Brown, Sylvie Chabaud, Adrian Cook, Silvia Forcat, Carol Fraser‐Browne, I. Latorzeff, Mahesh Parmar, Jayne F. Tierney	185
2	Early Outcome of a Phase I/II Clinical Trial (NCT03538899) of Gene-Corrected Autologous CD34+ Hematopoietic Cells and Low-Exposure Busulfan in Newly Diagnosed Patients with Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) 2020 ·Biology of Blood and Marrow Transplantation ·Morton J. Cowan, Jason Yu, (unknown), (unknown), Carol Fraser‐Browne, Janel Long-Boyle, Misako Kawahara, (unknown), (unknown), (unknown), Divya Punwani, Jasmeen Dara, Christopher C. Dvorak, Lori Broderick, Diana Hu, Holly Miller, Aleksandra Petrovič, Harry L. Malech, R. Scott McIvor, Jennifer M. Puck	13
3	Contour variation is a primary source of error when delivering post prostatectomy radiotherapy: Results of the Trans‐Tasman Radiation Oncology Group 08.03 Radiotherapy Adjuvant Versus Early Salvage (RAVES) benchmarking exercise 2019 ·Journal of Medical Imaging and Radiation Oncology ·(unknown), Michael Jameson, (unknown), Kirsty Wiltshire, Andrew Kneebone, Maria Pearse, Mark Sidhom, Colin Tang, Carol Fraser‐Browne, Lois Holloway, Annette Haworth	11
4	A Phase III Multi-Centre Randomised Trial comparing adjuvant versus early salvage Radiotherapy following a Radical Prostatectomy: Results of the TROG 08.03 and ANZUP “RAVES” Trial 2019 ·International Journal of Radiation OncologyBiologyPhysics ·Andrew Kneebone, Carol Fraser‐Browne, (unknown), Gillian Duchesne, Richard Fisher, Mark Frydenberg, Annette Haworth, Alan Herschtal, David Joseph, Tee Lim, Jarad Martin, Jeremy Millar, Mark Sidhom, Nigel Spry, Colin Tang, Susan Turner, Scott Williams, (unknown), Henry H. Woo, Maria Pearse	30
5	Adjuvant or salvage radiotherapy for the treatment of localised prostate cancer? A prospectively planned aggregate data meta-analysis 2019 ·Annals of Oncology ·Claire L. Vale, Meryem Brihoum, Sylvie Chabaud, Adrian Cook, David J. Fisher, Silvia Forcat, Carol Fraser‐Browne, Alan Herschtal, Andrew Kneebone, Soazig Nénan, Chris Parker, Mahesh Parmar, Maria Pearse, Pierre Richaud, Ewelina Rogozińska, Paul Sargos, Matthew R. Sydes, Jayne F. Tierney	31
6	Humidification mitigates acute mucosal toxicity during radiotherapy when factoring volumetric parameters. Trans Tasman Radiation Oncology Group (TROG) RadioHUM 07.03 substudy 2017 ·Oral Oncology ·Andrew Macann, Fariza Fauzi, John B. Simpson, Giuseppe Sasso, Hedley Krawitz, Carol Fraser‐Browne, Juliane Manitz, Andrea Raith	6
7	Azacitidine Administration Following Hematopoietic Stem Cell Transplantation Is Safe and Feasible in Children with Acute Leukemia 2016 ·Blood ·Justin T. Wahlstrom, Biljana Horn, Carol Fraser‐Browne, (unknown), Ying Lu, Alexis Melton, Jennifer Willert, Christopher C. Dvorak	2
8	Optimizing Radiation Therapy Quality Assurance in Clinical Trials: A TROG 08.03 RAVES Substudy 2015 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Andrew Kneebone, (unknown), Maria Pearse, Mark Sidhom, Colin Tang, Kirsty Wiltshire, Annette Haworth, Carol Fraser‐Browne, Jarad Martin	7
9	Do Screening Trial Recruitment Logs Accurately Reflect the Eligibility Criteria of a Given Clinical Trial? Early Lessons from the RAVES 0803 Trial 2014 ·Clinical Oncology ·Puma Sundaresan, Sandra Turner, Andrew Kneebone, Maria Pearse, Carol Fraser‐Browne, Henry H. Woo	5
10	A P hase III trial to investigate the timing of radiotherapy for prostate cancer with high‐risk features: background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage ( RAVES ) trial 2014 ·British Journal of Urology ·Maria Pearse, Carol Fraser‐Browne, Ian D. Davis, Gillian Duchesne, Richard Fisher, Mark Frydenberg, Annette Haworth, Chakiath Jose, David Joseph, Tee Lim, John Matthews, Jeremy Millar, Mark Sidhom, Nigel Spry, Colin Tang, Sandra Turner, Scott Williams, Kirsty Wiltshire, Henry H. Woo, Andrew Kneebone	80
11	Phase 3 Trial of Domiciliary Humidification to Mitigate Acute Mucosal Toxicity During Radiation Therapy for Head-and-Neck Cancer: First Report of Trans Tasman Radiation Oncology Group (TROG) 07.03 RadioHUM Study 2014 ·International Journal of Radiation OncologyBiologyPhysics ·Andrew Macann, Tsien Fua, Chris Milross, Sandro Porceddu, Michael Penniment, Chris Wratten, Hedley Krawitz, Michael Poulsen, Colin Tang, Randall P. Morton, K Hay, (unknown), Melanie L. Bell, Madeleine King, Carol Fraser‐Browne, Hans Hockey	8
12	Dovitinib in first-line metastatic renal cell carcinoma and correlation of efficacy with tumor gene status: A phase II clinical trial. 2014 ·Journal of Clinical Oncology ·Reuben Broom, George Dranitsaris, Carol Fraser‐Browne, (unknown), (unknown), (unknown), Paul Oei, (unknown), Mark J. McKeage, Nicola J. Mitchell, (unknown), Peter C.C. Fong	1
13	What is optimal timing of post prostatectomy radiotherapy? Is adjuvant radiotherapy equivalent to early salvage radiotherapy? The “RAVES” phase III randomized clinical trial. 2012 ·Journal of Clinical Oncology ·Maria Pearse, Andrew Kneebone, Gillian Duchesne, Richard Fisher, Carol Fraser‐Browne, Mark Frydenberg, Annette Haworth, Chakiath Jose, David Joseph, Tee Lim, John Matthews, Jeremy Millar, Mark Sidhom, Nigel Spry, Colin Tang, Sandra Turner, Scott Williams, Kirsty Wiltshire, Henry H. Woo, Ian D. Davis	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact